2. • A condition that occurs during pregnancy if
a blood and her
blood. Mother’s body create Rh
antibodies against the baby’s blood.
• Also known as haemolytic disease of the
fetus and newborn(HDFN).
Oct-15 2Rhesus Incompatibility
3. Introduction
• Rh-Ag are found on the surfaces of the RBCs may
cause isoimmunization.
• System used to designate Rh-Ag is the Fisher CDE
system.
• D-antigen, the most powerful Rh factor.
possess it- Rh +ve ; lack- Rh –ve
• Exposure of Rh-ve ppl to even small amounts of
Rh+ve cells can result in the production of anti-D
alloantibody– Rh sensitization/isoimmunization
Oct-15 Rhesus Incompatibility 3
4. Pathogenesis
Oct-15 Rhesus Incompatibility 4
1. Rh-ve mother carrying Rh+ve
fetus
2. Entry of fetus Rh+ve RBC into
maternal circulation
3. Development of Rh antibodies
by the mother
5. 1. Rh-ve mother carrying Rh+ve
fetus
• The chance of having Rh+ve fetus from
Rh+ve father ranges from 50% (if the father
is heterozygous) to 100% (if the father is
homozygous).
• Non paternity explains the development of
hemolytic disease of the newborn.
Oct-15 Rhesus Incompatibility 5
6. 2. Entry of the fetal Rh+ve RBC into
maternal circulation
• Transfusion of incompatible blood (rare)
• Fetomaternal hemorrhage(through leaks in the
placenta- 3rd stage):
Spontaneous/ induced abortion
Ectopic gestation
Antepartum hemorrhage: abruptio placenta,
amniocentesis, abdominal trauma, external cephalic
version.
• Worsen fetomaternal bleeding during labour are manual
removal of placenta, twin delivery and caeserian section.
• Fetal RBC are detected in the maternal circulation in 6%
in the 1st trimester, 15% in the 2nd trimester and 30% in
the 3rd trimester.
Oct-15 Rhesus Incompatibility 6
7. 3. Development of Rh antibodies by
the mother
• Initially – Ig M (big Ig can’t pass the placental
barrier).
• Fetomaternal bleeding in the subsequent
pregnancies results in the anamenstic reaction
producing Ig G (can pass placental barrier)
• Transfer of Ig G develops hemolytic disease of
the newborn and hydrops fetalis, antibodies
mediated destruction of the fetal RBCs.
• First neonate is usually spared but subsequent
Rh +ve fetuses are affected.
Oct-15 Rhesus Incompatibility 7
8. Risks of Rh incompatibility effect
Oct-15 Rhesus Incompatibility 8
Rh+ve father Rh-ve mother
1st Rh+ve baby
Usually unaffected
Rh+ve cells
Miscarriage/ Termination
of pregnancy
Ectopic pregnancy
Amniocentesis
Antepartum haemorrhage
Delivery of placenta
Rhesus antibodies
Pass to 2nd Rh+ve baby
Hemolysis of Rh +ve cells
Fetal Anemia
Hydrops fetalisIntrauterine transfusion
Postnatal exchange transfusionTreatment
9. Effects on the fetus and the newborn
• Hemolytic anemia
• Progressive anemia which eventually leads
to congestive HF and tissue hypoxia
• Portal HPT ~ obstruction of the portal veins
• Hydrop fetalis- generalized edema
• Kernicterus- unconjugated bilirubin crosses
the BBB and damages the basal ganglia
• Jaundice-⬆bilirubin in infant’s blood
Oct-15 9Rhesus Incompatibility
10. Signs in an unborn baby
• If the baby develops rhesus disease while still
in the womb, they may become anaemic
because their RBCs are being destroyed faster
than usual by the antibodies. If the anaemic is
severe, internal swelling may result.
Oct-15 10Rhesus Incompatibility
11. Signs in a newborn baby
• Hemolytic anemia
₋ Pale,
₋ increased breathing rate,
₋ poor feeding
• Jaundice
₋ Dark skin
₋ Yellow sclera, palms and soles
• Kernicterus
₋ Motor sensory and mental deficiencies
Oct-15 Rhesus Incompatibility 11
13. Investigations:
• At the first antenatal visit, all women are
screened for blood and Rh type.
• If a woman has Rh-negative blood, the
paternal blood type and zygosity (if paternity
is certain) are determined. If the father has
Rh-positive blood, maternal Rh antibody titres
are measured at 26 to 28 weeks.
• Maternal serum antibody titre is a guide to
disease severity.
Oct-15 Rhesus Incompatibility 13
14. Investigations:
• If antibody levels rise, the baby should be
examined for signs of anaemia.
• Fetal middle cerebral artery (MCA) blood flow is
measured at intervals of 1 to 2 weeks depending
on titres and patient history. The purpose is to
detect high-output heart failure and fetal anaemia.
• Using MCA doppler: the peak of MCA velocity
– Rise - high probability of anemia
Oct-15 Rhesus Incompatibility 14
Anti-D level Outcome
<4IU/mL HDFN unlikely
4-15IU/mL Moderate risk of HDFN
>15IU/mL High risk of hydrops fetalis
15. • Spectral photometry of amniotic fluid - used to measure the
level of bilirubin as an indirect indicator of fetal haemolysis.
• Ultrasound examination of the fetus at risk for Rh
incompatibility may reveal subcutaneous oedema, ascites,
pleural effusion, or pericardial effusion, all of which are
consistent with severe fetal anaemia in an affected fetus.
• A rosette test can be used to rule out significant
fetomaternal haemorrhage. If results are positive, a
Kleihauer-Betke (acid elution) test or flow cytometry can
measure the amount of fetal blood in the maternal
circulation.
Oct-15 Rhesus Incompatibility 15
Investigations:
17. Management of Rh-ve unsensitized
pregnancy
I. Identification of pregnancies at risk at the initial
ANC visit.
– Determine blood group & Rh factor and indirect
coombs test for antibody screening for all
pregnant mothers.
II. Management of unsensitized pregnancy
• Repeat indirect coombs test at 28 weeks and at
36 weeks. If negative consider antepartum
prophylaxis with 300 micrograms of anti D
gamma globulin at 28 weeks. If positive manage
as sensitized pregnancy.
Oct-15 17Rhesus Incompatibility
18. Management of Rh-ve unsensitized
pregnancy
• Provide anti D prophylaxis in cases with amniocentesis,
APH, external cephalic version.
• Following delivery determine blood group of the newborn
and antibody screening. If the newborn is Rh negative no
further treatment is needed. If antibody screen is positive
monitor the newborn for haemolysis and manage next
pregnancy as sensitized. If newborn is Rh negative and
antibody screen is negative, provide anti D gamma globulin
within 72 hours. The usual dose is 300 micrograms but
ideally should be determined by the extent of
fetomaternal hemorrhage. This is done by performing
Kleihauer Betke test (acid elusion test). For abortion of less
than 12 weeks gestation the dose is 50 micrograms.
Oct-15 18Rhesus Incompatibility
19. Management of sensitized mother
Oct-15 19Rhesus Incompatibility
• Measurement of antibody levels in titers at
regular intervals,
• Amniocentesis for bilirubin levels
• Serial ultrasound for detection of hydrops and
management of neonatal anemia and
hyperbilirubinemia.
• Therefore, referral of these women is the
correct approach at health center level.
20. Treatment
• Intrauterine transfusion
• Elect time of delivery
• Exchange transfusion after delivery
• Phototherapy after delivery
• Top-up transfusion
(Hb falls below 7g/dl, prophylactic :oral folate)
Oct-15 20Rhesus Incompatibility
21. Intrauterine transfusion
• The fetus can die in utero from severe anaemia and
hydrops before he can be delivered.
• An intrauterine transfusion can prolong the life in utero
of a fetus to a gestation where the risks of prematurity
are estimated as being less than those of the Rh disease.
This can be done by an:
1. Intraperitoneal transfusion guided by ultrasound.
2. Umbilical vein transfusion guided by ultrasound.
• Rh-negative blood is either transfused under ultrasound
control. Repeat as necessary, according to amniotic
optical density, or fetal haematocrit. The intravenous
route is becoming increasingly the preferred method.
Oct-15 Rhesus Incompatibility 21
22. Choose time of induction and best
method of delivery
• Balance the risks of prematurity (too soon) with
that of worsening Rh disease (too late).
• Consider the risks of vaginal delivery and be
prepared for a lower segment Caesarean section
(LSCS).
• Usually done only after 34 weeks of gestation.
• The paediatric team should be in close and a
senior paediatrician present at the delivery
• fresh Rh-negative blood available.
Oct-15 Rhesus Incompatibility 22
23. Resuscitation and Exchange transfusion
• Good resuscitation is
essential. In an anaemic and
premature infant, lung
disease is common. It can
be due to:
Surfactant deficiency at
very early delivery.
Pulmonary oedema from
anaemia and
hypoproteinaemia.
Hypoplastic lungs
secondary to pleural
effusions.
• In severe Rh haemolytic
disease of the newborn, an
umbilical artery catheter
should be inserted as soon
as possible to assess and
control PaO2 and pH.
• Central venous pressure
should be measured.
Drain pleural effusions and
ascites at resuscitation.
Oct-15 Rhesus Incompatibility 23
24. Indication for exchange
Transfusion:
1. Early: Decision mainly based
on cord haemoglobin
(in addition consider history of
previously affected babies).
• Cord haemoglobin <12g/dl.
• Strongly positive Coombs’ test.
• Cord bilirubin >85mmol/l.
2. Late: Usually done for
hyperbilirubinaemia.
• The aims:
Treat anaemia.
Washes out IgG antibodies.
Decreases degree of
haemolysis.
Removes bilirubin.
Prevents kernicterus.
Oct-15 Rhesus Incompatibility 24
Resuscitation and Exchange transfusion
25. Phototherapy
• Placing newborn baby under a halogen or
fluorescent lamp with their eyes covered.
• Lowers the bilirubin levels in the baby’s blood
through photo-oxidation.
• During phototherapy, intravenous hydration is
required.
Oct-15 Rhesus Incompatibility 25
26. Prevention and Prophylaxis
• anti-D immunoglobulin to all Rh-negative women at 28
and 34 weeks routinely-RAADP;
• Or give anti-D immunoglobulin
if she has a:
Therapeutic abortion.
Spontaneous abortion/ectopic pregnancy.
Amniocentesis.
Any bleeding in pregnancy/threatened miscarriage.
ECV.
After delivery at any gestation within 72Hours.
Oct-15 26Rhesus Incompatibility